Renal Stents Market Size
The global renal stents market size reached US$ 1.19 Billion in 2024 from US$ 1.12 Billion in 2023 and is expected to reach US$ 2.08 Billion by 2033, growing at a CAGR of 6.5% during the forecast period 2025-2033.
Renal Stents Market Overview
The renal stents market is defined by complex market dynamics, where clinical skepticism coexists with clear procedural demand in high-risk subgroups. Vendors are navigating this landscape by introducing technological refinements, including drug-eluting coatings, covered stents for perforation risk, and lower-profile systems designed for tortuous anatomies, that improve durability and procedural safety. Competitive intensity remains moderate, with players differentiating via evidence-based positioning, niche indication labeling, and strategic collaborations with imaging and catheter companies. As a result, the market operates less as a volume-driven device segment and more as a value-driven specialty ecosystem, where growth depends on targeted innovation, physician education, and aligning outcomes with payer and guideline expectations.
Renal Stents Market Executive Summary
Renal Stents Market Dynamics
Drivers:
Rising prevalence of renovascular hypertension and chronic kidney disease is significantly driving the renal stents market growth
The rising prevalence of renovascular hypertension and chronic kidney disease (CKD) is emerging as a significant driver of the renal stents market growth, largely because these conditions create a growing pool of high-risk patients who may benefit from targeted endovascular interventions. Renovascular hypertension, often caused by renal artery stenosis (RAS), is notoriously difficult to control with conventional antihypertensive drugs, particularly in patients with comorbid diabetes, obesity, and metabolic syndrome.
The global CKD burden continues to rise, with approximately 700 million people estimated to have CKD worldwide according to the National Institutes of Health (NIH), and an increasing number progressing to end-stage renal disease requiring dialysis or transplant. In this context, stenting offers a minimally invasive approach to preserve kidney function in cases of ischemic nephropathy caused by RAS, which is particularly important given the high cost and morbidity associated with dialysis.
In renal transplant patients, post-transplant RAS can lead to graft dysfunction, and stenting has become a frontline, graft-saving therapy. Recent registry studies and case series highlight that covered balloon-expandable stents, such as iCast, have demonstrated encouraging safety and efficacy in TRAS management, cementing their role in clinical practice. This trend is reinforced by the aging global population, which is more prone to atherosclerotic disease affecting renal arteries, thereby increasing the incidence of renovascular hypertension and CKD-linked complications. Combined, these dynamics position renal stents not as a routine intervention for all hypertension cases, but as a critical therapeutic option in carefully selected, high-risk cohorts, driving steady, niche market growth.
Restraints:
The risk of procedural complications is hampering the growth of the renal stents market
The risk of procedural complications remains one of the strongest factors hampering the growth of the renal stents market, as safety concerns continue to shape physician and payer reluctance. Renal stenting, while minimally invasive, carries risks such as arterial dissection, thrombosis, distal embolization, perforation, and contrast-induced nephropathy, all of which can be particularly dangerous in patients already compromised by chronic kidney disease. Restenosis is another frequent complication, often requiring repeat interventions that undermine the perceived durability of the procedure.
Even covered stents, while useful in preventing perforation and treating dissections, add complexity and cost, and complications such as stent migration or occlusion have been documented in case reports. These risks have contributed to guideline caution, with professional societies advising against routine use of renal stents outside well-defined high-risk groups. As a result, physicians often opt for aggressive medical management as the first-line therapy, reserving stenting only for transplant rescue or severe, refractory cases. This risk-benefit imbalance continues to dampen procedural volumes, restrict market expansion, and slow investment in large-scale innovation, leaving renal stents positioned as a niche intervention rather than a mainstream vascular therapy.
Renal Stents Market, Segment Analysis
The global renal stents market is segmented based on product type, material, application, end-user, and region.
The renal atherosclerotic disease segment from the application is dominating the renal stents market with a 23.90% share in 2024
The renal atherosclerotic disease prevalence is rising with the aging population, hypertension, diabetes, and cardiovascular comorbidities, making it the largest target group for renal stenting. Although large trials like ASTRAL and CORAL cast doubt on routine stenting, recent clinical practice has shown that selected high-risk subgroups of patients with recurrent flash pulmonary edema, refractory hypertension, or progressive ischemic nephropathy benefit significantly from revascularization, thereby sustaining demand. Registries and observational studies continue to validate stenting in these carefully defined patient populations, reinforcing the atherosclerotic segment’s clinical importance.
To address restenosis and peri-procedural risks common in atherosclerotic lesions, manufacturers have introduced specialized devices such as the Formula 418 Renal Balloon-Expandable Stent by Cook Medical for use in patients with atherosclerotic disease of the renal arteries following suboptimal percutaneous transluminal renal angioplasty (PTRA) of a de novo or restenotic lesion. These approvals demonstrate the segment’s commercial weight, as dedicated renal stent systems are largely designed with atherosclerotic disease in mind.
Renal Stents Market Geographical Share
North America is expected to dominate the global renal stents market with a 42.69% in 2024
North America is the dominant region in the renal stents market, driven by its high burden of atherosclerotic renal disease, resistant hypertension, and chronic kidney disease, all of which increase the prevalence of renal artery stenosis (RAS). The US, in particular, has a large patient pool of elderly individuals with diabetes, hypertension, and CKD, making it the single largest market for renal stenting procedures.
Additionally, North America’s leadership is also driven by its robust regulatory and reimbursement environment, which has enabled the approval and adoption of dedicated renal stent systems. The Formula 418 Renal Balloon-Expandable Stent (Cook Medical), Express LD Renal Stent System (Boston Scientific), and Herculink Elite Rapid Exchange Renal Stent System (Abbott Vascular) are all FDA-approved devices specifically indicated for renal artery use, underscoring the region’s product availability.
Clinical practice here is shaped by ongoing research, with US-based registries and real-world evidence programs continuing to evaluate outcomes in high-risk subgroups, helping refine stenting’s role despite the cautious interpretation of RCTs like ASTRAL and CORAL. The strong presence of interventional cardiology and radiology programs in leading US hospitals ensures that procedural expertise and infrastructure are readily available, further sustaining market share.
Renal Stents Market Competitive Landscape
Top companies in the renal stents market include Cook Medical, Boston Scientific Corporation, Abbott, optimed Medical Instruments GmbH and Blue Neem Medical Devices Private Limited, among others.
Renal Stents Market Scope
Metrics | Details | |
CAGR | 6.5% | |
Market Size Available for Years | 2022-2033 | |
Estimation Forecast Period | 2025-2033 | |
Revenue Units | Value (US$ Bn) | |
Segments Covered | Product Type | Balloon-Expandable Stents, Self-Expanding Stents and Others |
Material | Metal Stents, Polymer Stents, Composite Material Stents and Others | |
Application | Renal Atherosclerotic Disease, Renal Obstruction, Kidney Stone Management, Renal Artery Stenosis, Chronic Kidney Disease and Others | |
End-User | Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Academic and Research Institutes and Others | |
Regions Covered | North America, Europe, Asia-Pacific, South America and the Middle East & Africa | |
For more details on this report – Request for Sample
The global renal stents market report delivers a detailed analysis with 55 key tables, more than 63 visually impactful figures, and 167 pages of expert insights, providing a complete view of the market landscape.
Suggestions for Related Report
For more medical device-related reports, please click here
